ImmuCell Announces Preliminary Q1 2026 Sales Growth of 28.4%

On April 8, 2026, ImmuCell Corporation announced preliminary, unaudited sales results for the first quarter ended March 31, 2026. The company reported total product sales of $10.4 million, representing a 28.4% increase compared to $8.1 million in the same period of 2025. Growth was primarily driven by domestic sales, which rose 35.7% to $9.7 million, and strong performance from the Tri-Shield First Defense product line, which saw a 38.5% increase to $7.9 million. Conversely, international sales declined by 30.2% to $0.6 million. Management attributed the positive results to seasonal demand from the cow-calf segment and improved manufacturing strategies following previous production backlogs. To support continued growth, ImmuCell expanded its commercial team, hiring two domestic field sales managers and a leader for international efforts. The company plans to host a conference call on May 15, 2026, to discuss the full unaudited financial results for the quarter.